ADMA Biologics is trading 4.55% down at $9.34 after Berger Montague announced an investigation into potential fiduciary-duty breaches by the board, including allegations of channel stuffing despite declining ASCENIV demand.
- The probe adds to recent securities-fraud litigation concerns.
- Broader U.S. markets moved higher after softer-than-expected July PPI, but company-specific legal pressure outweighed supportive macro sentiment.